Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

BACKGROUND: The aberrant activation of the PI3K/mTOR signaling circuitry is one of the most frequently dysregulated signaling events in head and neck squamous cell carcinoma (HNSCC). Here, we conducted a single-arm, open-label phase IIa clinical trial in individuals with oral premalignant lesions (O...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutkind, J. Silvio, Molinolo, Alfredo A., Wu, Xingyu, Wang, Zhiyong, Nachmanson, Daniela, Harismendy, Olivier, Alexandrov, Ludmil B., Wuertz, Beverly R., Ondrey, Frank G., Laronde, Denise, Rock, Leigha D., Rosin, Miriam, Coffey, Charles, Butler, Valerie D., Bengtson, Lisa, Hsu, Chiu-Hsieh, Bauman, Julie E., Hewitt, Stephen M., Cohen, Ezra E.W., Chow, H-H. Sherry, Lippman, Scott M., Szabo, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492350/
https://www.ncbi.nlm.nih.gov/pubmed/34255745
http://dx.doi.org/10.1172/jci.insight.147096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492350/
https://www.ncbi.nlm.nih.gov/pubmed/34255745
http://dx.doi.org/10.1172/jci.insight.147096

Ejemplares similares